Skip to main content

Table 1 Baseline characteristics

From: Efficacy and safety of pyrotinib in advanced lung adenocarcinoma with HER2 mutations: a multicenter, single-arm, phase II trial

Characteristic
Age, years
  Median (range) 62 (31–85)
Sex, n (%)
  Male 37 (47.4)
  Female 41 (52.6)
ECOG performance status, n (%)
  0 15 (19.2)
  1 56 (71.8)
  2 7 (9.0)
Histology, n (%)
  Adenocarcinoma 78 (100)
Stage, n (%)
  IV 78 (100)
Brain metastases, n (%)
  No 58 (74.4)
  Yes 20 (25.6)
Smoking status, n (%)
  Former 22 (28.2)
  Never 51 (65.4)
  Unknown 5 (6.4)
EGFR mutation status, n (%)
  Positive 6 (7.7)
  Negative 72 (92.3)
ALK fusion status, n (%)
  Positive 0
  Negative 78 (100)
Pyrotinib treatment line, n (%)
  1 23 (29.5)
  2 15 (19.2)
  ≥ 3 40 (51.3)
Previous afatinib therapy
  Yes 21 (26.9)
  No 57 (73.1)
HER2 mutation, n (%)
  Exon 20 mutation 62 (79.5)
  Non-exon 20 mutation 16 (20.5)
  1. ECOG Eastern Cooperative Oncology Group